Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Massachusetts General Hospital

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1480
Shown on this page
12
Current sort
Recently updated
Campus scope
Massachusetts General Hospital, Boston, MA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Massachusetts General Hospital, Boston, MA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 841–852 of 1,480 matching trials with a site at Massachusetts General Hospital, Boston, MA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1Phase 2 Interventional

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

NCT05462106
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
Interventions
Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b
Biological
Lead sponsor
AC Immune SA
Industry
Eligibility
35 Years to 85 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
13
States / cities
Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 4, 2026, 2:14 PM EST
Recruiting Not applicable Interventional

Cognitive Rehabilitation for Victims of War and Related Traumas With Traumatic Brain Injury and Cognitive Impairment

NCT06839079
Status at this site: Recruiting
View directory record Official record
Conditions
TBI (Traumatic Brain Injury), Cognitive Symptoms
Interventions
A Trauma-informed, Paraprofessional Delivered Virtual Cognitive Rehabilitation Program
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Nov 4, 2026, 2:14 PM EST
Recruiting Phase 1 Interventional

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

NCT07315113
Status at this site: Not yet recruiting
View directory record Official record
Conditions
EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients
Interventions
NXP900, Osimertinib
Drug
Lead sponsor
Nuvectis Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Calverton, Maryland • Boston, Massachusetts • Eugene, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Nov 4, 2026, 2:14 PM EST
Recruiting Phase 2 Interventional

EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)

NCT07202000
Status at this site: Recruiting
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Activin ligand-trap biological therapy, Placebo, Normal Saline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Nov 4, 2026, 2:14 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

A Novel Approach to Upper Extremity Amputation to Augment Volitional Control and Restore Proprioception

NCT03882073
Status at this site: Recruiting
View directory record Official record
Conditions
Amputation
Interventions
Modified amputation procedure, Standard amputation procedure
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
4
States / cities
Bethesda, Maryland • Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Nov 4, 2026, 2:14 PM EST
Not yet recruiting Phase 2 Interventional

Verapamil Effect in Cystic Fibrosis-related Dysglycemia

NCT07688070
Site status not listed — check the official record
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes, Cystic Fibrosis (CF), Abnormal Glucose Tolerance
Interventions
Verapamil Hydrochloride
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Nov 4, 2026, 2:14 PM EST
Recruiting Phase 4 Interventional Accepts healthy volunteers

GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH

NCT06003153
Status at this site: Recruiting
View directory record Official record
Conditions
Genetic Predisposition, Metabolic Diseases, Type 2 Diabetes
Interventions
oral semaglutide, Mixed Meal Tolerance Test (MMTT)
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 4, 2026, 2:14 PM EST
Active, not recruiting Phase 3 Interventional

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

NCT05409066
Site status not listed — check the official record
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Epcoritamab, Rituximab, Lenalidomide
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
31
States / cities
Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 4, 2026, 2:14 PM EST
Active, not recruiting Phase 2 Interventional Results available

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]

NCT03747120
Site status not listed — check the official record
View directory record Official record
Conditions
HER2-positive Breast Cancer, Breast Cancer
Interventions
Paclitaxel, Trastuzumab, Pertuzumab, Pembrolizumab
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Albuquerque, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 4, 2026, 2:14 PM EST
Active, not recruiting Not applicable Interventional

Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial

NCT03706833
Site status not listed — check the official record
View directory record Official record
Conditions
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Interventions
Edwards PASCAL System, Abbott Mitraclip System
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
1,247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
63
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 4, 2026, 2:14 PM EST
Recruiting Not applicable Interventional

Behavioral Intervention for Youth to Promote Vaping Cessation

NCT06765291
Status at this site: Recruiting
View directory record Official record
Conditions
Vaping, Vaping Teens, Nicotine Dependence
Interventions
QuitVaping, This is Quitting (TIQ)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 19 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Nov 4, 2026, 2:14 PM EST
Recruiting Not applicable Interventional

Healthy Aging as Black Adults, In It Together: a Comparative Effectiveness Study of Chronic Pain and Cognitive Decline

NCT06246929
Status at this site: Recruiting
View directory record Official record
Conditions
Chronic Pain, Physical Activity, Older Adults, Mild Cognitive Impairment
Interventions
MBCT+w, ALED
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Nov 4, 2026, 2:14 PM EST

About this Massachusetts General Hospital institution page

What this page lists
ClinicalTrials.gov records that list Massachusetts General Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Massachusetts General Hospital at any site, browse by condition, or browse by U.S. city.